DUBLIN--(BUSINESS WIRE)--The "Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2018,
provides comprehensive information on the therapeutics under development
for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.
The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also
reviews of key players involved in therapeutic development for Bile Duct
Cancer (Cholangiocarcinoma) and features dormant and discontinued
projects.
The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5,
63, 30, 16 and 3 respectively. Similarly, the Universities portfolio in
Phase II, Phase I and Preclinical stages comprises 2, 1 and 4 molecules,
respectively.
Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies Featured
- 4SC AG
- AbbVie Inc
- Advenchen Laboratories LLC
- Agios Pharmaceuticals Inc
- Ariad Pharmaceuticals Inc
- ArQule Inc
- AstraZeneca Plc
- Bavarian Nordic A/S
- Bayer AG
- Eddingpharm Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Fujifilm Holdings Corporation
- Genentech Inc
- Genoscience Pharma
- Incyte Corp
- Innopharmax Inc
- MediciNova Inc
- MedImmune LLC
- Merck & Co Inc
- Molecular Templates Inc
- NanoCarrier Co Ltd
- NormOxys Inc
- Novartis AG
- NuCana Plc
- PCI Biotech Holding ASA
- Pfizer Inc
- Pharma Mar SA
- Plexxikon Inc
- Senhwa Biosciences Inc
- Taris Biomedical LLC
- TCR2 Therapeutics Inc
-
and many more...
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/smcfwm/bile_duct_cancer?w=4
